Inito Unveils AI-Powered Fertility Reader for Precision Home Tracking

HOUSTON, TX – April 09, 2026

Inito, a company at the forefront of at-home diagnostics, has officially launched the InSight Wireless Reader, a new device poised to redefine fertility tracking from the comfort of home. The Wi-Fi enabled reader leverages patented technology to measure four key fertility hormones from a single urine strip, promising a level of precision previously confined to clinical laboratories. This launch marks a significant step in a rapidly growing market, where consumers are increasingly seeking detailed, actionable health data.

The device aims to move beyond the limitations of traditional ovulation prediction kits, which often provide a simple binary result based on a single hormone. By offering a comprehensive view of a user's hormonal cycle, Inito is providing a tool designed for the complexities of modern fertility journeys.

A New Era for At-Home Fertility Tracking

The at-home fertility tracking market, valued at over $790 million in 2024, is shifting from simple prediction to sophisticated monitoring. Inito's InSight reader is a prime example of this evolution. Instead of just tracking the Luteinizing Hormone (LH) to predict an ovulation window, the device measures estrogen (E3G), LH, the progesterone metabolite PdG, and Follicle-Stimulating Hormone (FSH) simultaneously. This multi-hormone approach allows users not only to identify their fertile window but also to confirm that ovulation actually occurred—a critical piece of information that most at-home tests cannot provide.

"When you’re trying to conceive, you don’t just want a result, you want to trust it," said Aayush Rai, Co-Founder of Inito, in the company's announcement. "We built InSight Wireless Reader to raise the standard for at-home hormone tracking in two ways: by improving how hormone levels are measured, and by making testing work better in real life."

This comprehensive data is crucial because, as the company notes, fertility is a sequence of hormonal events, not a single moment. Understanding the rise, peak, and fall of these four hormones across a cycle provides a much richer narrative of a person's reproductive health, which is especially valuable for those with irregular cycles or underlying conditions.

Under the Hood: The Technology Behind the Precision

At the heart of the InSight reader is Inito's patented Spectral Mapping technology, trained on a massive database of over 40 million hormone datapoints. The company claims this system delivers "lab-grade reliability" through several key innovations.

First, each fertility strip has four independent tracks to measure the hormones separately, a design intended to prevent the cross-reactivity and signal interference that can plague less advanced tests. Second, the reader employs a dual-signal verification process, using both fluorescence and visual colorimetric imaging to double-check each measurement. This allows the system to detect subtle hormone changes that might otherwise be missed.

Finally, the device captures the entire surface of the test strip over time, generating what Inito describes as a "100x richer signal" from every test. An advanced AI algorithm then processes this data, correcting for common real-world variables like ambient lighting and humidity that can affect test results.

The company's methodology is backed by peer-reviewed research. Published studies have validated Inito's accuracy, showing that its urinary hormone measurements correspond with blood hormone trends with 95% accuracy. It's important to note this refers to the pattern and direction of hormone changes over time, not an exact one-to-one match of absolute values between urine and serum. Furthermore, a PdG-based method demonstrated 92.2% precision in confirming ovulation among users testing at home, a key differentiator from tests that only predict it.

Navigating a Crowded Market

Inito enters a competitive landscape populated by established names and innovative newcomers. Its most direct competitor is likely Mira, which also offers a quantitative analysis of multiple fertility hormones. While both systems track E3G, LH, PdG, and FSH, Inito's introductory price of $99 for the reader and 15 strips undercuts many of Mira's starter kits, which can range from $199 to $229. The ongoing cost for Inito users will be approximately $49 for a new pack of 15 strips, which is comparable to competitor refill costs.

Compared to legacy brands like Clearblue, which typically offer qualitative "low," "high," or "peak" results for one or two hormones, Inito provides precise numerical values and graphed trends. This quantitative data offers a more granular view of a user's cycle. The device also stands apart from wearable trackers like the Ava bracelet or Oura Ring, which infer fertility status from indirect physiological markers like skin temperature and heart rate variability. Inito's system relies on the direct measurement of hormones in urine, a method generally considered by experts to have more direct evidence supporting its accuracy for ovulation tracking.

The product's eligibility for HSA/FSA reimbursement further enhances its accessibility, placing advanced diagnostic technology within reach for a broader consumer base.

Beyond Ovulation: Empowering Diverse Fertility Journeys

Perhaps the most significant impact of the InSight Wireless Reader lies in its potential to empower individuals navigating complex and often frustrating fertility paths. The detailed hormone patterns it generates are particularly beneficial for users with irregular cycles, Polycystic Ovary Syndrome (PCOS)-like conditions, or those who are post-pill or preparing for IVF. For these individuals, a simple "yes/no" ovulation test is often insufficient or misleading.

"As a physician, the most meaningful fertility conversations happen when we can review a patient’s full hormone pattern, not just a single lab result," noted Dr. Lora Shahine, an advisor at Inito. "Tools like the InSight Wireless Reader, which track hormone patterns across cycles, give patients accurate data so they can come into consultations feeling informed and confident." This full picture can lead to quicker decisions and more timely adjustments to care.

The new device also brings significant quality-of-life improvements. Built-in Wi-Fi means users can start a test and walk away, receiving a notification on their phone when the 10-minute analysis is complete, freeing them from being tethered to the device. Crucially, the InSight reader is compatible with both iOS and Android for the first time, opening up the platform to a much wider audience that was previously limited.

This launch is not just about a single product; it reflects Inito's broader ambition to expand the scope of at-home diagnostics. With over 20 patents and a growing global presence, the company has stated its intention to move into other areas of personal health, including monitoring testosterone, vitamins, and thyroid hormones, transforming the home into a hub for managing personal health.